CLDX (Celldex Therapeutics) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.23
GF Value $6.88
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Other Stockholders Equity?

Celldex Therapeutics CLDX +3.43% 57 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Celldex Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Celldex Therapeutics's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Celldex Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Celldex Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Other Stockholders Equity Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Celldex Therapeutics (CLDX) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Other Stockholders Equity too high?
Celldex Therapeutics' current Other Stockholders Equity is $0.00 Mil. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Other Stockholders Equity compare to IMNM and ELVN?
Celldex Therapeutics' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.23
Price
$6.88
GF Value